Last Price$82.42NASDAQ Closing Price as of 4:00PM ET 2/19/20
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change+3.12(3.93%)
Bid (Size)$81.01 (1)
Ask (Size)$81.99 (9)
Day Low / High$79.64 - 82.59
Volume1.9 M

Incyte, Eli Lily Say Baricitinib for Atopic Dermatitis Meets Targets in Late-Stage Trial

4:00PM ET 8/23/2019 MT Newswires
Incyte (INCY) and Eli Lilly (LLY) said on Friday a late-stage trial of baricitinib to treat moderate to severe atopic dermatitis (AD) in adults has met its primary endpoint in BREEZE-AD7, the third pivotal Phase 3 trial in the BREEZE-AD program to be completed in 2019.

Adding baricitinib to standard-of-care topical corticosteroids significantly improved disease severity, they said. Baricitinib is approved for the treatment of adults with moderately to severely active rheumatoid arthritis in more than 60 countries.

Price: 81.91, Change: -3.65, Percent Change: -4.27